Skip to content

Serotonin: all studies

Page 256 of 401: studies 2,551 to 2,560 of 4,006, newest first. Back to the serotonin overview

Research

Potential therapeutic use of ayahuasca: A literature review

Acta Amazonica 2024 Salvana Priscylla Manso Costa, Keith Cardoso Carvalho, Isabella Nunes Gomes et al. 4 citations

ABSTRACT Ayahuasca is a psychoactive decoction originally used in indigenous Amazonian culture. It consists of a dense brown liquid that most frequently results from the decoction of two plants native to the Amazon rainforest, Psychotria viridis (Rubiaceae) and Banisteriopsis caapi (Malpighiaceae). The composition of the decoction is variable, as several plant species can be used in its...

Antidepressants enter cells, organelles, and membranes.

Neuropsychopharmacology 2024 Zack Blumenfeld, Kallol Bera, Eero Castrén et al. 10 citations

We begin by summarizing several examples of antidepressants whose therapeutic actions begin when they encounter their targets in the cytoplasm or in the lumen of an organelle. These actions contrast with the prevailing view that most neuropharmacological actions begin when drugs engage their therapeutic targets at extracellular binding sites of plasma membrane targets-ion channels, receptors,...

Die subakuten Effekte des Psilocybin auf Persönlichkeit, Achtsamkeit und die Auflösung des Selbst

2024 Albert Lehr

Psychedelics are a class of drugs that can occasion similar changes in conscious ex- periences mediated via the G-protein coupled Serotonin 2A receptor. These changes vary from slight distortions in perceptions to pseudohallucinations and the experienced cessation of a personal self distinct from and necessary for conscious experience, known as ego-dissolution. Psychedelics produce positive...

Psilocybin Therapy for Depression: A Review of Current Molecular Knowledge

Journal of the Netherlands Society of Toxicology 2024 Marcha Verheijen 1 citation

Depression, affecting over 264 million people globally, presents significant treatment challenges, often due to the limited efficacy and adverse effects of traditional antidepressants and the accessibility issues associated with psychotherapy. Recent advancements in psychedelic-assisted therapy, particularly using psilocybin, a naturally occurring compound found in “magic mushrooms”, shows...

DOI: 10.61833/jnst.2024.0002 (opens in new tab) Full text (opens in new tab) Psilocybin Depression economics Current fluid Psychotherapist +1

Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms.

Neuroscience Applied 2024 Drummond E-Wen Mcculloch, Juan Pablo Lopez, Christina Dalla et al. 2 citations

Classical psychedelic drugs, e.g., psilocybin and LSD, stimulate the serotonin 2A receptor (5-HT2AR) and have recently been intensely investigated for their clinical effects in various brain disorders. At the ECNP "New Frontiers meeting" in March 2023, scientific experts in psychedelics met to identify key knowledge gaps in the mechanism of action of psychedelics as investigated using...

DOI: 10.1016/j.nsa.2023.103929 (opens in new tab) Full text (opens in new tab) Hallucinogen investigation Psychoactive drug research Entheogen research Psychedelic compounds +15

Impact of Altered Gut Microbiota on Ketamine-Induced Conditioned Place Preference in Mice.

Neuropsychiatric Disease and Treatment 2024 Chan Li, Chen Zhu, Genghong Tu et al. 4 citations

Ketamine is a drug of abuse worldwide and current treatments for ketamine abuse are inadequate. It is an urgent need to develop novel anti-addictive strategy. Since gut microbiota plays a crucial role in drug abuse, the present study investigates the impact and mechanisms of the gut microbiota in addictive behaviors induced by ketamine addiction. Conditioned place preference (CPP) was employed...

Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission: results from the ICEBERG study.

Frontiers in Psychiatry 2024 Albino J Oliveira-Maia, Benoit Rive, Yordan Godinov et al. 3 citations

Treatment resistant depression (TRD) affects approximately 10-30% of patients with major depressive disorder, and most patients with TRD do not respond to real-world treatments (RWT). Treatment with esketamine nasal spray (NS) plus a selective serotonin or serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) has significant long-term clinical benefit over RWT in patients with TRD. However,...

Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders.

Molecular Psychiatry 2024 Uriel Heresco-Levy, Bernard Lerer 17 citations

Modern research data suggest a therapeutic role for serotonergic psychedelics in depression and other neuropsychiatric disorders, although psychotomimetic effects may limit their widespread utilization. Serotonergic psychedelics enhance neuroplasticity via serotonin 2 A receptors (5HT2AR) activation and complex serotonergic-glutamatergic interactions involving the ionotropic glutamate...

Shared functional connectome fingerprints following ritualistic ayahuasca intake.

Neuroimage 2024 Pablo Mallaroni, Natasha L. Mason, Lilian Kloft et al. 17 citations

The knowledge that brain functional connectomes are unique and reliable has enabled behaviourally relevant inferences at a subject level. However, whether such "fingerprints" persist under altered states of consciousness is unknown. Ayahuasca is a potent serotonergic psychedelic which produces a widespread dysregulation of functional connectivity. Used communally in religious ceremonies, its...

DOI: 10.1016/j.neuroimage.2023.120480 (opens in new tab) Full text (opens in new tab) DMT Entheogens Brain connectivity connectome Neuroimaging FMRI +8

Brain dynamics predictive of response to psilocybin for treatment-resistant depression.

Brain Communications 2024 Jakub Vohryzek, Joana Cabral, Louis-David Lord et al. 33 citations

Psilocybin therapy for depression has started to show promise, yet the underlying causal mechanisms are not currently known. Here, we leveraged the differential outcome in responders and non-responders to psilocybin (10 and 25 mg, 7 days apart) therapy for depression-to gain new insights into regions and networks implicated in the restoration of healthy brain dynamics. We used large-scale brain...

DOI: 10.1093/braincomms/fcae049 (opens in new tab) Full text (opens in new tab) Large-scale brain modelling Psilocybin treatment Psilocybin therapy Neuroscience research +3